@article{TLCR24921,
author = {Jose Luis Perez-Gracia and Miguel F. Sanmamed and Ignacio Melero},
title = {Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {Recently, Forde et al. reported in the New England Journal of Medicine a pilot study in which two neoadjuvant doses of the PD-1 inhibitor nivolumab were administered in a preoperative fashion to 21 patients with untreated, surgically resectable early (stage I–IIIA) non-small cell lung cancer (NSCLC) (1). Surgery was performed 4 weeks after the first dose of nivolumab.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/24921}
}